Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.
Kasper Bruun KristensenDaniel Pilsgaard HenriksenNina Sahlertz KristiansenJesper HallasLars Christian LundPublished in: Diabetologia (2021)
Initiation of treatment with SGLT2Is was associated with a clinically significant reduced risk of incident and recurrent nephrolithiasis.